Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
Saved in:
| Title: | Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. |
|---|---|
| Authors: | Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jegede OA; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Grilley-Olson JE; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Lauring JD; Johns Hopkins School of Medicine, Baltimore, MD., Mitchell EP; Thomas Jefferson University, Philadelphia, PA., Zwiebel JA; National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; National Cancer Institute, Bethesda, MD., Rubinstein LV; National Cancer Institute, Bethesda, MD., Patton D; National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Kono SA; Colorado Permanente Medical Group, Lone Tree, CO., Ford JM; Stanford University, Stanford, CA., Garcia AA; Louisiana State University Health Science Center, New Orleans, LA., Sui XD; Providence Regional Cancer System, Lacey, WA., Siegel RD; Bon Secours St Francis Hospital, Greenville, SC., Slomovitz BM; University of Miami, Miami, FL., Conley BA; National Cancer Institute, Bethesda, MD., Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX., Harris LN; National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100424. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
